We are live on ! Find out more
DA

DCF Advisers Portfolio holdings

AUM $375M
1-Year Est. Return 72.65%
This Fund
S&P 500
This Quarter Est. Return
-1.84%
1 Year Est. Return
+72.65%
3 Year Est. Return
+156.29%
5 Year Est. Return
+218.72%
10 Year Est. Return
–
AUM
$227M
AUM Growth
-$55.7M
Cap. Flow
-$49.7M
Cap. Flow %
-21.93%
Top 10 Hldgs %
50.08%
Holding
105
New
12
Increased
23
Reduced
19
Closed
24

Top Buys

Rank Stock Value
1
IMPL
Impel Pharmaceuticals Inc. Common Stock
IMPL
+$2.18M
2
ARGX icon
argenx
ARGX
+$1.58M
3
ALT icon
Altimmune
ALT
+$1.14M
4
AAPL icon
Apple
AAPL
+$1.1M
5
XNCR icon
Xencor
XNCR
+$1.08M

Top Sells

Rank Stock Value
1
GOOG icon
Alphabet (Google) Class C
GOOG
+$5.93M
2
KIN
Kindred Biosciences, Inc.
KIN
+$3.32M
3
ORCL icon
Oracle
ORCL
+$1.99M
4
GLD icon
SPDR Gold Trust
GLD
+$1.67M
5
AMD icon
Advanced Micro Devices
AMD
+$1.53M

Sector Composition

Rank Sector Weight
1 Healthcare 38.05%
2 Technology 12.14%
3 Communication Services 8.72%
4 Financials 5.36%
5 Consumer Discretionary 4.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
$29M 12.79%
67,500
-76,000
-53% -$33.5M
ITCI
2
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$14.1M 6.24%
379,000
+4,000
+1% +$139K
MU icon
3
Micron Technology
MU
$930B
$12.6M 5.56%
177,500
+7,500
+4% +$563K
GOOG icon
4
Alphabet (Google) Class C
GOOG
$4.36T
$11.6M 5.12%
87,000
-43,000
-33% -$5.93M
REGN icon
5
Regeneron Pharmaceuticals
REGN
$78.5B
$9.68M 4.27%
16,000
+500
+3% +$310K
ABBV icon
6
AbbVie
ABBV
$443B
$8.39M 3.7%
77,750
+750
+1% +$85.7K
ARGX icon
7
argenx
ARGX
$53.4B
$7.55M 3.33%
25,000
+5,000
+25% +$1.58M
XNCR icon
8
Xencor
XNCR
$1.5B
$7.51M 3.32%
230,000
+33,000
+17% +$1.08M
SPY icon
9
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$790B
$6.65M 2.94%
+15,500
New +$6.84M
BAC icon
10
Bank of America
BAC
$435B
$6.37M 2.81%
150,000
– –
VZ icon
11
Verizon
VZ
$195B
$5.4M 2.38%
100,000
– –
GDX icon
12
VanEck Gold Miners ETF
GDX
$22.7B
$5.16M 2.28%
175,000
-10,000
-5% -$326K
TPB icon
13
Turning Point Brands
TPB
$1.45B
$4.82M 2.13%
101,000
-21,250
-17% -$1.02M
INCY icon
14
Incyte
INCY
$24.2B
$4.82M 2.13%
70,000
+9,000
+15% +$684K
GM icon
15
General Motors
GM
$80.4B
$4.74M 2.09%
90,000
-10,000
-10% -$531K
C icon
16
Citigroup
C
$222B
$4.56M 2.01%
65,000
– –
PRTA icon
17
Prothena Corp
PRTA
$425M
$4.27M 1.89%
60,000
-1,750
-3% -$109K
AMD icon
18
Advanced Micro Devices
AMD
$776B
$4.12M 1.82%
40,000
-15,000
-27% -$1.53M
GLD icon
19
SPDR Gold Trust
GLD
$131B
$3.69M 1.63%
22,500
-10,000
-31% -$1.67M
ORCL icon
20
Oracle
ORCL
$374B
$3.48M 1.54%
40,000
-22,500
-36% -$1.99M
IAU icon
21
iShares Gold Trust
IAU
$62.9B
$3.34M 1.47%
100,000
– –
ALNY icon
22
Alnylam Pharmaceuticals
ALNY
$27.5B
$3.3M 1.46%
17,500
– –
PFE icon
23
Pfizer
PFE
$143B
$2.8M 1.23%
65,000
– –
ALT icon
24
Altimmune
ALT
$552M
$2.71M 1.19%
239,200
+93,450
+64% +$1.14M
GLD icon
25
CALL
SPDR Gold Trust
GLD
$131B
$2.63M 1.16%
16,000
+6,000
+60% +$1M
1
2 3 4 5

Similar funds

JIC
JRM Investment Counsel Omaha, Nebraska $375M AUM 13.43% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return
AIM
Access Investment Management Atlanta, Georgia $376M AUM 17.2% 1-Year Est. Return
MWM
McMill Wealth Management Norfolk, Nebraska $376M AUM 14.46% 1-Year Est. Return
RCP
RIT Capital Partners London, United Kingdom $374M AUM 25.18% 1-Year Est. Return
HPM
Helix Partners Management New York $374M AUM 136.73% 1-Year Est. Return
CAG
Compass Advisory Group Melville, New York $374M AUM 14.59% 1-Year Est. Return
LWMNY
Landmark Wealth Management (New York) Melville, New York $373M AUM 12.01% 1-Year Est. Return

DCF Advisers's Q3 2021 Portfolio in Review

As of Q3 2021, DCF Advisers held 105 positions worth $227M, down 20% from $282M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

DCF Advisers withdrew a net $49.7M in Q3 2021, closing 24 positions and reducing 19 holdings. Its most notable exit was Kindred Biosciences, Inc., an estimated $3.32M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 29% a quarter earlier, followed by Technology and Communication Services.

Against the trend, DCF Advisers opened a new position in Impel Pharmaceuticals Inc. Common Stock worth $1.83M.

  • DCF Advisers's largest Q3 2021 buy was Impel Pharmaceuticals Inc. Common Stock: 150,000 shares worth $1.83M.
  • DCF Advisers added most to argenx in Q3 2021, an estimated $1.58M increase.
  • DCF Advisers's biggest Q3 2021 reduction was Alphabet (Google) Class C, cutting an estimated $5.93M.
  • DCF Advisers fully exited Kindred Biosciences, Inc. in Q3 2021, selling an estimated $3.32M.
  • DCF Advisers's ten largest holdings make up 50% of its $227M portfolio in Q3 2021.
  • DCF Advisers opened 12 new positions and closed 24 in Q3 2021.
  • DCF Advisers's portfolio value fell 20% quarter-over-quarter to $227M.

Based on DCF Advisers's 13F filing for Q3 2021, filed 15 Nov 2021.